Carlsmed's preliminary Q4 revenue rises 61% to $15.2 mln

Carlsmed

12/01/2026 13:13

Overview

Medical tech firm's preliminary Q4 2025 revenue grew 61% yr/yr to $15.2 mln

Preliminary full-year 2025 revenue rose 86% to $50.5 mln

Company added 101 new surgeon users in 2025, a 61% increase

Outlook

Carlsmed anticipates growing recognition and adoption of aprevo in 2026

Company focuses on operational excellence for next growth phase in 2026

Result Drivers

SURGEON USER BASE - Carlsmed added 101 new surgeon users in 2025, a 61% increase, driving revenue growth

APREVO PLATFORM - Increased adoption of aprevo platform technology contributed to Q4 revenue growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
$15.20 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Carlsmed Inc is $20.00, about 57.6% above its January 9 closing price of $12.69

Press Release: ID:nGNX9jtcKP

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)